LILLY ELI & CO Form SC 13G/A February 11, 2010

> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

> > SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Eli Lilly and Company (Name of Issuer)

Common Stock (Title of Class of Securities)

> 532457108 (CUSIP Number)

December 31, 2009 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [] Rule 13d-1(c) [] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSII	2: 53245	7108		Page 1 of 4	
1	NAMES OI I.R.S. Capital)			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			(a)	
3	SEC USE	ONL	Y	(b)	
4	CITIZEN				
	Delawar	е			
		5	SOLE VOTING POWER		
	BER OF HARES FICIALL WNED BY EACH ORTING ERSON ITH:		2,042,700		
SI		6	SHARED VOTING POWER NONE		
Y OI		7	SOLE DISPOSITIVE POWER		
REPO			87,117,891		
W		8	SHARED DISPOSITIVE POWER		
			NONE		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	87,117, 13d-4	891	Beneficial ownership disclaimed pursua	nt to Rule	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
	7.6%				

IA

** A division of Capital Research and Management Company (CRMC)

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CUSIP: 532457108 Page 2 of 4 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Schedule 13G Under the Securities Exchange Act of 1934 Amendment No. 2 Name of Issuer: Item 1(a) Eli Lilly and Company Item 1(b) Address of Issuer's Principal Executive Offices: Lilly Corporate Center Indianapolis, IN 46285 Item 2(a) Name of Person(s) Filing: Capital World Investors Item 2(b) Address of Principal Business Office or, if none, Residence: 333 South Hope Street Los Angeles, CA 90071 Item 2(c) Citizenship: N/A Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 532457108 Item 3 If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: An investment adviser in accordance with (e) [X] section 240.13d-1(b)(1)(ii)(E). Ttem 4 Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: (b) Percent of class: (C) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: (ii) Shared power to vote or to direct the vote: (iii) Sole power to dispose or to direct the disposition of: Shared power to dispose or to direct the disposition of: (iv)

See page 2

Capital World Investors is deemed to be the beneficial owner of

87,117,891 shares or 7.6% of the 1,149,023,000 shares of Common Stock believed to be outstanding as a result of CRMC acting as investment adviser to various investment companies registered under Section 8 of the Investment Company Act of 1940.

CUSIP: 532457108

Page 3 of 4

- Item 5 Ownership of Five Percent or Less of a Class. If this
 statement is being filed to report the fact that as of the date
 hereof the reporting person has ceased to be the beneficial
 owner of more than five percent of the class of securities,
 check the following: []
- Item 6 Ownership of More than Five Percent on Behalf of Another Person: One or more clients of Capital World Investors have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock of Eli Lilly and Company.
- Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person: N/A
- Item 8 $$\rm Identification$ and Classification of Members of the Group: $$\rm N/A$$
- Item 9 Notice of Dissolution of Group: N/A
- Item 10 Certification

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 8, 2010

Signature:	Robert W.	Lovelace***
Name/Title:	Robert W.	Lovelace - Senior Vice
	President	
	Capital W	orld Investors

***By /s/ Walter R. Burkley Walter R. Burkley Attorney-in-fact

Signed pursuant to a Power of Attorney dated December 21, 2007 included as an Exhibit to Schedule 13G filed with the

Securities and Exchange Commission by Capital World Investors on January 10, 2008 with respect to Lowes Companies, Incorporated.

CUSIP: 532457108

Page 4 of 4